Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied ... Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA ... The Globe and Mail: Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Markets Insider: Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye ...

Understanding the Context

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye ... The American Journal of Managed Care: Antimalarial Drug Plus Adalimumab Aids Hair Regrowth in Lichen Planopilaris The combination of the biologic adalimumab and hydroxychloroquine may be responsible for the improvement in lichen planopilaris, including the hair regrowth, according to the study. When adalimumab ... Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for ...

Key Insights

What is the treatment for a large scalp lesion diagnosed as lichen planus? Can these lesions evolve into squamous cell carcinoma (SCC) or other malignancy? โ€” Clarence R. Sanders, MD, Gallatin, Tenn. FinanzNachrichten.de: Roivant Sciences: Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Roivant Sciences: Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)